SUTRO BIOPHARMA, INC. Net Change in Cash
SUTRO BIOPHARMA, INC. (STRO) reported Net Change in Cash of -$3.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $15.55M.
- SUTRO BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$84.08M.
- SUTRO BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$4.07M, a 126.71% decline year-over-year.
- SUTRO BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $15.22M.
- SUTRO BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$132.17M, a 209.21% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $121.02M, a 449.75% increase from fiscal 2023.
- SUTRO BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $22.01M, a 30.72% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $16.84M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.79M 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $15.55M 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | -$132.17M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | -$124.38M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$126.28M 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | -$84.08M 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | $121.02M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $105.30M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $21.50M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$4.07M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $22.01M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $34.58M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $187.84M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $15.22M 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $16.84M 10-K · filed 2025-03-13 | |||
| 2022-09-30 | $66.36M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $48.70M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$1.51M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$175.74M 10-K · filed 2024-03-25 | |||
| 2021-09-30 | -$175.44M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | -$149.76M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | -$150.33M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $202.05M 10-K · filed 2023-03-30 | |||
| 2020-09-30 | $60.27M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $60.39M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $38.60M 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | -$120.34M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | -$113.34M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | -$105.91M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$98.68M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $103.28M 10-K · filed 2021-03-18 | |||
| 2018-09-30 | $19.33M 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | $10.17M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |